BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 38874014)

  • 1. The dynamic duo: A narrative review on the synergy between stereotactic body radiotherapy and immunotherapy in lung cancer treatment (Review).
    Cheng SH; Tu KY; Lee HH
    Oncol Rep; 2024 Jul; 52(1):. PubMed ID: 38874014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoints Inhibitors and SRS/SBRT Synergy in Metastatic Non-Small-Cell Lung Cancer and Melanoma: A Systematic Review.
    Rodríguez Plá M; Dualde Beltrán D; Ferrer Albiach E
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769050
    [No Abstract]   [Full Text] [Related]  

  • 3. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.
    Chen Y; Gao M; Huang Z; Yu J; Meng X
    J Hematol Oncol; 2020 Jul; 13(1):105. PubMed ID: 32723363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review.
    Chicas-Sett R; Morales-Orue I; Castilla-Martinez J; Zafra-Martin J; Kannemann A; Blanco J; Lloret M; Lara PC
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31052488
    [No Abstract]   [Full Text] [Related]  

  • 5. The Combined Use of SBRT and Immunotherapy-a Literature Review.
    Lubas MJ; Kumar SS
    Curr Oncol Rep; 2020 Sep; 22(12):117. PubMed ID: 32929678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Report of an abscopal effect induced by stereotactic body radiotherapy and nivolumab in a patient with metastatic non-small cell lung cancer.
    Britschgi C; Riesterer O; Burger IA; Guckenberger M; Curioni-Fontecedro A
    Radiat Oncol; 2018 May; 13(1):102. PubMed ID: 29855323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Stereotactic Body Radiation Therapy on Diverse Organ Lesions in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Zhu KK; Wei JL; Xu YH; Li J; Rao XR; Xu YZ; Xing BY; Zhang SJ; Chen LC; Dong XR; Zhang S; Li ZY; Liu CW; Meng R; Wu G
    Curr Med Sci; 2023 Apr; 43(2):344-359. PubMed ID: 37002471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Prospective Trial Evaluating the Safety and Systemic Response From the Concurrent Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Non-Small Cell Lung Cancer.
    Mattes MD; Eubank TD; Almubarak M; Wen S; Marano GD; Jacobson GM; Ma PC
    Clin Lung Cancer; 2021 Jul; 22(4):268-273. PubMed ID: 33608212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation and immunotherapy combinations in non-small cell lung cancer.
    Azghadi S; Daly ME
    Cancer Treat Res Commun; 2021; 26():100298. PubMed ID: 33387868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of immunotherapy in stage III nonsmall cell lung cancer.
    Wrona A
    Curr Opin Oncol; 2019 Jan; 31(1):18-23. PubMed ID: 30489337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases.
    Corrao G; Marvaso G; Ferrara R; Lo Russo G; Gugliandolo SG; Piperno G; Spaggiari L; De Marinis F; Orecchia R; Garassino MC; Jereczek-Fossa BA
    Lung Cancer; 2020 Apr; 142():70-79. PubMed ID: 32120227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and clinical efficacy of immune checkpoint inhibition and stereotactic body radiotherapy in patients with spine metastasis.
    Lee E; Chen X; LeCompte MC; Kleinberg LR; Hales RK; Voong KR; Forde PM; Brahmer JR; Markowski MC; Lipson EJ; Lee SH; Bydon A; Lo SL; Lubelski D; Redmond KJ
    J Neurosurg Spine; 2023 Aug; 39(2):278-286. PubMed ID: 37148233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
    Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
    Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergizing systemic responses by combining immunotherapy with radiotherapy in metastatic non-small cell lung cancer: The potential of the abscopal effect.
    Theelen WS; de Jong MC; Baas P
    Lung Cancer; 2020 Apr; 142():106-113. PubMed ID: 32126451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Stereotactic body radiotherapy: Passing fad or revolution?].
    Vallard A; Vial N; Jmour O; Rehailia-Blanchard A; Trone JC; Sotton S; Daguenet E; Guy JB; Magné N
    Bull Cancer; 2020 Feb; 107(2):244-253. PubMed ID: 31864665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Blood Biomarkers for Response Prediction and Monitoring of Stereotactic Ablative Radiotherapy and Immunotherapy in Metastatic Oligoprogressive Lung Cancer.
    Zafra J; Onieva JL; Oliver J; Garrido-Barros M; González-Hernández A; Martínez-Gálvez B; Román A; Ordóñez-Marmolejo R; Pérez-Ruiz E; Benítez JC; Mesas A; Vera A; Chicas-Sett R; Rueda-Domínguez A; Barragán I
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses.
    Caetano MS; Younes AI; Barsoumian HB; Quigley M; Menon H; Gao C; Spires T; Reilly TP; Cadena AP; Cushman TR; Schoenhals JE; Li A; Nguyen QN; Cortez MA; Welsh JW
    Clin Cancer Res; 2019 Dec; 25(24):7576-7584. PubMed ID: 31540976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiotherapy and Immunotherapy Combinations for Lung Cancer.
    Agrawal V; Benjamin KT; Ko EC
    Curr Oncol Rep; 2020 Nov; 23(1):4. PubMed ID: 33215306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mono-institutional phase 2 study of innovative Stereotactic Body RadioTherapy targeting PArtial Tumor HYpoxic (SBRT-PATHY) clonogenic cells in unresectable bulky non-small cell lung cancer: profound non-targeted effects by sparing peri-tumoral immune microenvironment.
    Tubin S; Khan MK; Salerno G; Mourad WF; Yan W; Jeremic B
    Radiat Oncol; 2019 Nov; 14(1):212. PubMed ID: 31771654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moving Immunotherapy Into the Treatment of Resectable Non-Small Cell Lung Cancer.
    Chaft JE; Dziadziuszko R; Haddock Lobo Goulart B
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432500. PubMed ID: 38788177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.